Comparative Pharmacology
Head-to-head clinical analysis: IODIXANOL versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODIXANOL versus IOPAMIDOL 250 IN PLASTIC CONTAINER.
IODIXANOL vs IOPAMIDOL-250 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodixanol is a nonionic, iso-osmolar iodinated contrast agent that attenuates X-rays, allowing visualization of vascular structures and organ parenchyma. It does not bind to or interact with specific receptors.
Iodinated radiographic contrast medium that attenuates X-rays and provides radiopacity in vascular and body cavities. It does not undergo significant pharmacological activity.
Intravenous injection of 270-350 mg iodine/kg (0.5-1.0 mL/kg of 270 mg I/mL solution) for CT; 300-400 mg iodine/kg for angiography. Administer as bolus or infusion per procedure.
250 mg iodine/mL; 1.5 mL/kg (up to 100 mL) IV bolus or infusion for CT imaging.
None Documented
None Documented
Clinical Note
moderateIodixanol + Metformin
"The risk or severity of adverse effects can be increased when Iodixanol is combined with Metformin."
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 10-12 hours, requiring dose adjustment and monitoring.
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 30+ hours in severe impairment), dictating contrast dosing intervals
Primarily renal: approximately 97% of the administered dose is excreted unchanged in the urine within 24 hours via glomerular filtration. Less than 3% is excreted in feces via biliary elimination.
Renal: 95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent